QuANTUM-First: phase 3, double-blind, placebo-controlled study of quizartinib in combination with induction and consolidation chemotherapy, and as maintenance therapy in patients (pts) with newly diagnosed (NDx) FLT3-ITD acute myeloid leukemia (AML)

Autores de IIS La Fe

• Pau Montesinos Fernández

  Autor

Participantes ajenos a IIS La Fe

• Schlenk, R
• Dombret, H
• Amadori, S
• Levis, M
• Sekeres, MA
• Cortes, J
• Perl, A
• Zernovak, O
• Mires, D
• Ge, N
• Zhang, H
• Hanyok, J
• Macintyre, S
• Gokmen, S
• Kobayashi, K
• Erba, H

Grupos

• Hematología y Hemoterapia

Abstract

Abstract no disponible